DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/3dtrtp/parkinsons) has announced the addition of the "Parkinson's Disease Therapeutics in Major Developed Markets to 2021: Early Pipeline Shifts Towards Disease-Modifying Therapies, while Short Term Growth Driven by Long-Acting Symptomatic Treatments" report to their offering.
The global Parkinson's Disease (PD) prevalence was estimated at 16.1 million in 2011, and after Alzheimer's disease it is the second most common neurodegenerative disease worldwide.
Parkinson's Disease (PD) is a progressive disease and, although not fatal, it can develop severe symptoms and complications that significantly impact upon the patient's quality of life. Symptoms for each stage can be categorized into early, moderate and advanced stages. Major motor symptoms of Parkinson's Disease (PD) include tremors and difficulty walking. Parkinson's Disease (PD) also gives rise to non-motor symptoms, such as dementia, depression, hallucinations and loss of taste and smell.
There are several different drug classes available to relieve Parkinson's Disease (PD) symptoms. The aim is for treatments to increase dopamine levels, which is substantially diminished in brains affected by Parkinson's Disease (PD). The most common therapies include levodopa, dopamine agonists and Monoamine Oxidase-B (MAO-B) inhibitors, with the choice of therapies dependent on patient symptoms and lifestyle. As the disease develops, the medication will need to be taken more strictly, due to the effect of drugs wearing off (known as off- time), which causes symptoms to return before the next dose.
With the current marketed drugs focusing primarily on symptomatic relief, Parkinson's Disease (PD) remains incurable, with a huge unmet need for disease-modifying therapies. However, due to the lack of clearly established clinical trial methodologies, replication of the benefits demonstrated by neuroprotective agents in the laboratory to human trials has proved challenging. More importantly, due to an incomplete understanding of the underlying mechanisms that cause the disease, a viable therapeutic target to halt or slow disease progression is currently not in scope, which limits the effectiveness of current product development programs.
Key Topics Covered:
1 Tables & Figures
2 Introduction
2.1 Disease Introduction
2.2 Symptoms
2.3 Etiology
2.4 Pathophysiology
2.5 Epidemiology
2.6 Disease Stages
2.7 Co-morbidities and Complications
2.8 Diagnosis
2.9 Assessment of Disease Severity
2.10 Treatment
2.11 Treatment Algorithm
3 Marketed Products
3.1 Overview
3.2 Comparative Efficacy and Safety
4 Pipeline for Parkinson's Disease
4.1 Overview
4.2 Pipeline Distribution by Mechanism of Action/Molecular Target
4.3 Clinical Trials
4.4 Promising Pipeline Molecules
4.5 Heatmaps of Safety and Efficacy for Parkinson's Disease Pipeline and Marketed Products
4.6 Pipeline Product Heat Map and Product Competitiveness Framework
5 Market Forecast to 2021
5.1 Geographical Markets
5.2 Drivers and Barriers
6 Strategic Consolidations
6.1 Major Co-Development Deals
6.2 Major Licensing Deals
7 Appendix
Companies Mentioned
- 23andMe
- Catalent Pharma Solutions
- Cephalon
- Dainippon Sumitomo Pharma
- Dexcel Pharma
- Genentech
- Hitachi
- MJFF
- MedGenesis Therapeutix
- Mesoblast
- Neuropore Therapies
- Pfizer
- Prothena
- Sellas Life Sciences
- TechnoPhage
- UbiQ
- Ubiquigent
For more information visit http://www.researchandmarkets.com/research/3dtrtp/parkinsons
